Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: A propensity-adjusted analysis

Journal of Viral Hepatitis

Volumn 18, Issue 7, 2011, Pages 493-505

  Di Martino, V ^a   Crouzet, J ^a,b   Hillon, P ^c,d   Thevenot T ^a,b   Minello, A ^c,d   Monnet, E ^a,b  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c HÔPITAL DU BOCAGE   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

antiviral therapy; hepatitis C; liver related mortality; non liver related mortality; outcome; population based cohort study; survival bias

Indexed keywords

ALCOHOL CONSUMPTION; ANTIBODY SCREENING; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; EVALUATION AND FOLLOW UP; FATALITY; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROPENSITY SCORE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALCOHOL DRINKING; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 79959585302     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01476.x     Document Type: Article

References (45)

1. Shepard CW, Finelli L, Alter MJ,. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567. (Pubitemid 41196755)
2. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
3. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 19: 341.
4. Seeff LB,. Natural history of chronic hepatitis C. Hepatology 2002; 36 (Suppl. 1): S35-S46. (Pubitemid 35253462)
5. Tong MJ, el-Farra NS, Reikes AR, Co RL,. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
6. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T,. Natural course of chronic hepatitis C. Am J Gastroenterol 1993; 88: 240-243. (Pubitemid 23053477)
7. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132: 105-111. (Pubitemid 30044176)
8. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33: 455-463. (Pubitemid 32119036)
9. Kenny-Walsh E,. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-1233. (Pubitemid 29181642)
10. Poynard T, Bedossa P, Opolon P,. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 22: 349.
11. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J,. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 2001; 34: 730-739. (Pubitemid 32488789)
12. Deuffic-Burban S, Poynard T, Valleron AJ,. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepat 2002; 9: 114-122. (Pubitemid 36002474)
13. Di Martino V, Lebray P, Myers RP, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 2004; 40: 1426-1433. (Pubitemid 39657018)
14. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-1058. (Pubitemid 29458296)
15. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34: 1193-1199. (Pubitemid 33096592)
16. Corrao G, Arico S,. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998; 27: 914-919. (Pubitemid 28160474)
17. Monto A, Patel K, Bostrom A, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 2004; 39: 826-834. (Pubitemid 38337664)
18. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821-829.
19. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 15: 127.
20. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472. (Pubitemid 27078833)
21. Poynard T, Opolon P,. Hepatitis C: somber views of natural history and optimistic views of interferon treatment? Hepatology 1998; 27: 1443-1444. (Pubitemid 28227877)
22. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313. (Pubitemid 34465173)
23. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 26: 347.
24. Osella AR, Sonzogni L, Cavallini A, et al. Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in southern Italy: a population-based study. J Clin Microbiol 1999; 37: 2371-2372. (Pubitemid 29277814)
25. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB,. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 1372-1380. (Pubitemid 39457763)
26. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999; 42: 2204-2212. (Pubitemid 30263607)
27. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-848. (Pubitemid 38298332)
28. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 18: 328.
29. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 11: 347.
30. Austin PC, Platt RW,. Survivor treatment bias, treatment selection bias, and propensity scores in observational research. J Clin Epidemiol 2010; 63: 136-138.
31. Bedossa P,. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20. (Pubitemid 24196485)
32. Korn EL, Graubard BI, Midthune D,. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997; 145: 72-80. (Pubitemid 27009060)
33. Tleyjeh IM, Ghomrawi HM, Steckelberg JM, et al. Propensity score analysis with a time-dependent intervention is an acceptable although not an optimal analytical approach when treatment selection bias and survivor bias coexist. J Clin Epidemiol 2010; 63: 139-140.
34. Lu B,. Propensity score matching with time-dependent covariates. Biometrics 2005; 61: 721-728.
35. Bergstralh EJ, Kosanke JL, Jacobsen SJ,. Software for optimal matching in observational studies. Epidemiology 1996; 7: 331-332.
36. Lin DY, Wei LJ,. The robust inference for the proportional hazards model. J Am Stat Assoc 1989; 84: 1074-1078.
37. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D,. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997; 26: 485-490. (Pubitemid 27328330)
38. Harrel FH, editor. Regression Modeling Strategies with Application to Linear Models, Logistic Regression and Survival Analysis. New York: Springer-Verlag, 2001.
39. D'Agostino Jr RB,. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 15: 17.
40. Sorensen HT, Friis S, Olsen JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998; 28: 921-925. (Pubitemid 28450250)
41. Torregrosa M, Aguade S, Dos L, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005; 42: 68-74. (Pubitemid 40038902)
42. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A,. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 17: 137.
43. Puoti C, Castellacci R, Montagnese F, et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002; 37: 117-123. (Pubitemid 34713063)
44. US Preventive Services Task Force,. Screening for hepatitis C virus infection in adults: recommendation statement. Ann Intern Med 2004; 140: 462-464.
45. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-2441.